Prevalence of potential drug–drug interactions in outpatients on treatment with parenteral antineoplastic drugs

Background As live expectancy and cancer incidence growing, polypharmacy in oncology patients is also increasing, raising the risk of developing potential drug–drug interactions. Objective To assess the prevalence of clinically relevant potential drug–drug interactions among cancer patients who rece...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical pharmacy 2019-12, Vol.41 (6), p.1429-1433
Main Authors: Castro-Manzanares, M., do Pazo-Oubiña, F., Rodríguez-Rincón, R. M.
Format: Article
Language:English
Subjects:
Adult
Age
Aged
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Antineoplastic drugs
Cancer therapies
Contraindications
Drug dosages
Drug interaction
Drug Interactions
Expectancy
Female
Hematology
Hospitals
Humans
Injections
Internal Medicine
Male
Medicine
Medicine & Public Health
Middle Aged
Neoplasms - drug therapy
Oncology
Outpatient care facilities
Outpatients
Patients
Pharmacy
Polypharmacy
Prescription drugs
Prevalence
Retrospective Studies
Risk reduction
Short Research Report
Software
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background As live expectancy and cancer incidence growing, polypharmacy in oncology patients is also increasing, raising the risk of developing potential drug–drug interactions. Objective To assess the prevalence of clinically relevant potential drug–drug interactions among cancer patients who receive parenteral treatment at our outpatient clinic. Method Retrospective observational study which included randomly selected patients who had received parenteral treatment from November 1st 2016 to January 31st 2017. Interactions were checked in 3 databases, and classified as clinically relevant or not and in three categories of severity: contraindicated, consider modification or monitor. Results A total of 273 patients were included; of which seventy three (26.7%) had at least one clinically relevant potential drug–drug interaction. Amongst them, 54 (74%) had at least one classified as monitor treatment, 50 (68.5%) as contraindicated and 26 (35.6%) as consider modification. The number of chronic prescriptions was associated with a higher risk of drug interactions. Conclusion Around one in four patients on treatment with parenteral antineoplastic drugs presented a clinically relevant potential drug–drug interaction. A systematic assessment of drug–drug interactions should be implemented to reduce the risk of clinically relevant drug–drug interactions.
ISSN:2210-7703
2210-7711
DOI:10.1007/s11096-019-00910-7